RHOH and neoplasm: Biodistribution data revealed that tTF-pHLIP was specifically accumulated in the tumor 8 hours after intravenous administration, but little or no accumulation in heart, liver, spleen, kidney or lung (Supplementary Figure S4), suggesting a high specificity of tTF-pHLIP for tumor tissue.